Does melatonin lower testosterone levels? In healthy adult men taking typical sleep-support doses (0.5–5 mg), the evidence does not show a meaningful, sustained reduction in total or free testosterone. Isolated studies report transient dips or seasonal shifts, but controlled trials and meta-analyses generally find no clinically important suppression at standard doses. The picture changes at high doses, in specific populations, and when melatonin is combined with other hormonal inputs.

That answer comes with real caveats. Melatonin is not hormonally inert. It interacts with the hypothalamic-pituitary-gonadal (HPG) axis, the adrenal axis, and the pineal-gonadal signaling network. Whether those interactions translate into lower testosterone depends on dose, timing, duration, age, baseline health, and what else is happening in the body. The sections below separate mechanism from measurement, and signal from noise.

The HPG axis and where melatonin acts

Testosterone production is governed by a three-tier loop. The hypothalamus releases gonadotropin-releasing hormone (GnRH). The anterior pituitary responds by secreting luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH then drives testicular Leydig cells to synthesize testosterone from cholesterol. Any agent that lowers testosterone must do one of three things: suppress GnRH pulse frequency, blunt LH secretion, or impair Leydig-cell steroidogenesis directly.

Melatonin has plausible access to all three nodes. Pineal melatonin is not a peripheral hormone acting at a distance only; melatonin receptors (MT1 and MT2) are expressed in the hypothalamus, pituitary, and testes. MT1 signaling in the pituitary can modulate LH release, and experimental work shows melatonin can reduce GnRH pulsatility in hypothalamic preparations. At the testicular level, melatonin receptor activation has been linked to altered steroidogenic enzyme expression, including changes in the StAR protein that shuttles cholesterol into mitochondria.

Why doesn't this produce obvious suppression in most men? Three reasons. First, endogenous melatonin peaks at night, when LH pulsatility is already low and testosterone synthesis is partially decoupled from acute LH drive. Second, melatonin's hypothalamic effects are modulated by photoperiod and by gonadal steroid feedback, so the system buffers against small perturbations. Third, exogenous doses used for sleep are often below the threshold needed to produce sustained receptor occupancy at the pituitary and gonadal level. In plain terms, melatonin can touch the controls, but the body tends to hold the setpoint.

A counterintuitive detail worth flagging: melatonin's effect on the reproductive axis is often biphasic. Low-to-moderate exposure can be neutral or even mildly protective of Leydig-cell function under oxidative stress, while high or prolonged exposure shifts toward suppression. The dose-response curve is not a straight line downward.

Quantified context: what trials actually measure

The best evidence comes from controlled trials and meta-analyses rather than single measurements. A 2023 systematic review and meta-analysis of randomized controlled trials in men found no significant effect of melatonin supplementation on total testosterone when pooled across studies, though heterogeneity was substantial and several included trials used doses above 6 mg. Earlier trials in healthy young men reported small nocturnal reductions in LH and testosterone during melatonin administration, but the changes were transient and returned toward baseline after discontinuation.

Typical numbers help calibrate. Normal adult male total testosterone runs roughly 300–1,000 ng/dL, with a diurnal pattern peaking in early morning. A clinically meaningful suppression is usually framed as a drop large enough to shift a man below the reference range or to produce symptoms. Most reported melatonin-associated changes fall within the 5–15 percent range and within assay variability, which is substantial: immunoassays can differ by 10–20 percent between platforms, and single measurements are unreliable for detecting small shifts.

Two thresholds need reconciling. The Endocrine Society's reference range for total testosterone in healthy nonobese young men is approximately 264–916 ng/dL, while many laboratories report 300–1,000 ng/dL. A 10 percent drop from 600 ng/dL lands at 540 ng/dL, still well within both ranges. The same 10 percent drop from 280 ng/dL crosses below the lower threshold. This is why baseline matters more than the average effect size. Men near the lower reference boundary have less room before a small suppression becomes clinically visible.

Timing matters too. Melatonin is usually taken 30–60 minutes before bed, which overlaps with the nocturnal LH trough. Studies sampling testosterone only at night may overstate suppression relative to morning samples, and studies sampling only in the morning may miss transient nocturnal changes. The measurement window is part of the result.

Edge cases: populations where the signal strengthens

Most healthy-adult data are reassuring. The picture is less clean in specific groups.

Adolescents during puberty: melatonin influences GnRH pulse generation, and the pubertal transition is a period of heightened sensitivity to reproductive-axis perturbations. Pediatric melatonin use for sleep disorders is common, and long-term gonadal monitoring is limited. Men with hypogonadism or borderline low testosterone: a small additional suppression may push them below threshold, and the clinical margin is narrow. Men on testosterone replacement therapy or gonadotropin suppression: exogenous androgens already suppress the HPG axis, and adding a centrally acting agent complicates interpretation. Shift workers and men with disrupted circadian rhythms: endogenous melatonin timing is already abnormal, and exogenous melatonin may interact unpredictably with an already-dysregulated axis. Men with obesity or metabolic syndrome: aromatase activity and insulin resistance alter testosterone metabolism, and melatonin's metabolic effects may change the net direction of the signal.

A professional caveat: much of the mechanistic evidence comes from animal models, particularly seasonal breeders like hamsters and sheep, where melatonin is a potent photoperiodic signal that shrinks the gonads. Humans are not seasonal breeders in the same sense, and extrapolating from rodent reproductive suppression to human testosterone is a category error unless the human data support it. They largely do not, at typical doses.

Misconceptions and the sleep confounder

The most common misconception is that because melatonin is a hormone, any dose must affect other hormones. Hormones act through receptor density, affinity, and feedback loops; a hormone with low receptor occupancy in a tissue has little functional effect there regardless of circulating concentration. Melatonin's reproductive receptors are present but not uniformly sensitive, and the body's feedback architecture dampens small perturbations.

The second misconception is that melatonin directly lowers testosterone when the real driver is sleep. Sleep restriction to 5 hours per night for one week has been shown to reduce daytime testosterone by 10–15 percent in healthy young men, a larger effect than most melatonin trials report. Melatonin improves sleep onset and duration in some people, which would tend to protect testosterone rather than lower it. Confounding by indication is common in observational data: men who take melatonin often have insomnia, sleep apnea, or shift-work schedules, all of which independently affect testosterone.

The third misconception is that higher doses are more effective and therefore more risky. Melatonin dose-response for sleep is flat above roughly 0.5–1 mg, and higher doses increase next-day grogginess and receptor desensitization without clear benefit. Physiologic dosing is closer to 0.3 mg than to 10 mg.

Practical actions and thresholds

If the goal is to support sleep without disturbing the reproductive axis, several concrete steps reduce risk.

Use the lowest effective dose: 0.5–1 mg taken 30–60 minutes before target bedtime is often sufficient; higher doses do not reliably improve sleep and increase exposure. Time it to the circadian window: taking melatonin during the day, when endogenous levels are low, produces a larger perturbation than nighttime dosing. Address sleep apnea and insomnia first: untreated sleep apnea lowers testosterone independently, and melatonin is not a substitute for diagnosis or treatment. Measure testosterone in the morning (before 10 a.m.) if concerned, and repeat on a second day; single measurements are unreliable. Avoid combining melatonin with other HPG-suppressing agents without clinical guidance, including opioids, glucocorticoids, and anabolic steroids. Discontinue and reassess if new symptoms appear: low libido, fatigue, or mood changes after starting melatonin warrant a conversation with a clinician rather than dose escalation.

A comparison of options helps frame melatonin against alternatives.

Approach Typical effect on testosterone Evidence quality Notes
Melatonin 0.5–1 mg at night Neutral to small transient change Moderate (RCTs, meta-analysis) Lowest exposure; preferred starting point
Melatonin 5–10 mg at night Small, usually transient reduction reported in some trials Moderate, heterogeneous Higher doses not more effective for sleep
Sleep extension to 7–8 hours Increase of roughly 10–15 percent in sleep-restricted men Good (controlled trials) Larger effect than most supplement interventions
Untreated sleep apnea Suppression proportional to severity Good Treatment (CPAP) restores much of the deficit
Testosterone replacement therapy Raises testosterone; suppresses endogenous LH/FSH Good Not comparable; different mechanism

A timeline table helps set expectations for what changes when.

Timeframe What is observed
Single night, 0.5–5 mg Transient nocturnal LH and testosterone dips in some studies
1–2 weeks of nightly use Most trials show return toward baseline; no cumulative suppression at standard doses
4–8 weeks Pooled meta-analytic effect near zero in healthy men
Discontinuation No rebound suppression reported; axis returns to prior state
Chronic high-dose use (months) Limited human data; animal data suggest possible sustained suppression at high exposure
Adolescents during puberty Insufficient long-term data; monitor clinically if used chronically
Men with hypogonadism Small additional suppression possible; baseline matters

Limitations of the evidence

The honest position is that the human literature is smaller and less rigorous than the confidence of online claims suggests. Many trials are short (days to weeks), use small samples, and rely on single testosterone measurements. Assay heterogeneity makes pooling difficult. Most studies enroll healthy young men, leaving older men, adolescents, and men with metabolic disease underrepresented. Publication bias favors positive findings, and null results are less likely to be reported.

There is also a mechanistic blind spot: melatonin's effects on the reproductive axis may depend on the photoperiod and on the timing of exposure relative to the light-dark cycle, variables that most trials do not control. Seasonal variation in testosterone, documented in some populations, complicates cross-study comparison.

What can be concluded with reasonable confidence is this: at typical sleep doses in healthy adult men, melatonin does not produce a clinically meaningful or sustained lowering of testosterone. At high doses, in vulnerable populations, or in combination with other hormonal inputs, small effects are plausible and warrant monitoring. The question is not whether melatonin can touch the axis, because it can, but whether the touch is strong enough and long enough to matter. For most users at standard doses, the answer is no.